Omalizumab (Xolair) in patients with steroid-resistant asthma: lessons to be learnt.
Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.
Thompson
Philip J
PJ
Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia. pjthomps@liwa.uwa.edu.au
Misso
Neil L
NL
Woods
John
J
D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D001980:Bronchi / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D004351:Drug Resistance / Q000276:immunology*; D005260:Female; D006801:Humans; D007378:Interleukins / Q000276:immunology; D000069444:Omalizumab; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D011965:Receptors, Glucocorticoid / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007378:Interleukins; D011965:Receptors, Glucocorticoid; D000069444:Omalizumab; D011239:Prednisolone